Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; melanoma Tethering T cell therapies to an inhibitor of the cholesterol metabolism enzyme SOAT could enhance the cell therapy’s efficacy against glioblastoma and melanoma. The T cells were engineered...

Chi-Med’s surufatinib approved in ChinaChina’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda surufatinib to treat non-pancreatic neuroendocrine tumors. The FGFR, VEGFR and CSF1R inhibitor is...

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The vesicles were collected from the supernatant of mature oligodendrocytes differentiated from mouse oligodendrocyte progenitor cells. In mouse models...

Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant...

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now...

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This...

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...